Skip to main content
OpenTrials
Completed

NCT Number: NCT03209687

The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles

The aim of this study is to test the hypothesis that addition of daily small dose of human menopausal gonadotropin (HMG) drug following oocytes retrieval could improve the fertility outcome in women undergoing in-vitro fertilization

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Department of Obstetrics and Gynecology, Kasr Al-Ainy hospital

Cairo, Greater Cairo, 11956, Egypt

About this study

The study will be conducted in the IVF unit of Cairo University. Females undergoing ICSI cycles in the age between 20 and 40 years will be allocated to one of 2 groups. Long agonist protocol will be used. Allocation to either one of 2 groups will be done on the day of oocytes retrieval. The first group will take (in addition to the routine care) daily human menopausal gonadotropin drug injection for 2 weeks. The second group will receive the routine care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females undergoing Intra-Cytoplasmic Sperm Injection (ICSI) cycles
  • Age between 20 and 40 years

Exclusion criteria

  • Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)

Treatment and study plan

human menopausal gonadotropin

Drug

Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles

Other names: Merional

Primary outcomes

  1. Live birth rate

    Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study

    The live birth rate will be calculated by a statistician for each group

Secondary outcomes

  1. Clinical pregnancy rate

    Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study

    The clinical pregnancy rate will be calculated by a statistician for each group

  2. Implantation rate

    Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study

    The implantation rate will be calculated by a statistician for each group

  3. Miscarriage rate

    Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study

    The miscarriage rate will be calculated by a statistician for each group

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Human Menopausal Gonadotropin as a Novel Addition to Luteal Phase Support in Down-regulated ICSI Cycles (RCT)

Important dates

Study start
2017
Primary completion
2024
Study completion
2024
First posted
Jul 6, 2017
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.